Headlines about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kura Oncology earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.6292359408761 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news articles that may have effected Accern’s rankings:
Shares of NASDAQ KURA traded down $0.65 during trading on Tuesday, hitting $17.35. The company had a trading volume of 222,142 shares, compared to its average volume of 308,109. The stock has a market capitalization of $617.04 million, a P/E ratio of -11.41 and a beta of 4.29. Kura Oncology has a 52 week low of $5.90 and a 52 week high of $24.02. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.37 and a current ratio of 12.37.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, May 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.11). research analysts forecast that Kura Oncology will post -1.75 earnings per share for the current year.
A number of equities research analysts have weighed in on KURA shares. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a research report on Wednesday, March 21st. BidaskClub downgraded Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 16th. ValuEngine upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Cann reaffirmed a “buy” rating and issued a $27.00 price target on shares of Kura Oncology in a report on Tuesday, April 17th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Kura Oncology presently has a consensus rating of “Buy” and a consensus target price of $22.00.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.